Xeris Biopharma

Observed headcount was 523 on September 8 and 537 on October 8, a gain of 14 or 2.7%; the latest reliable observed count was 537. Among 237 tracked employees, no inferred departures were first observed during the window, although one possible departure or employer-change signal requires review. This is a workforce observation, not a reconciliation of hires and departures.

Newly observed field roles cover rare-disease endocrinology in McAllen, Texas and the Princeton/New York area, rare-disease neurology in Arizona, and diabetes/endocrinology in Fort Worth, Texas and Harrisburg, Pennsylvania. The descriptions center on educating healthcare professionals, executing territory plans, identifying appropriate patients, addressing access and treatment barriers, and supporting therapy initiation or prescription conversion. These are job openings rather than evidence that

The listed internship roles include CMC and manufacturing-science support for product development, regulatory documentation, process-development trials and technology transfer; medical-affairs operations and regional scientific exchange; paid-media campaign execution and sales enablement; and commercial-systems work evaluating data, automation and AI use cases. The breadth of functions is observable recruiting intent for temporary internship roles, not evidence of permanent staffing or completed